Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer’s Measurement

In Barbara Osimani & Adam La Caze, Uncertainty in Pharmacology (2020)
  Copy   BIBTEX

Abstract

In biomedical measurement, biomarkers are used to achieve reliable prediction of, and useful causal information about patient outcomes while minimizing complexity of measurement, resources, and invasiveness. A biomarker is an assayable metric that discloses the status of a biological process of interest, be it normative, pathophysiological, or in response to intervention. The greatest utility from biomarkers comes from their ability to help clinicians (and researchers) make and evaluate clinical decisions. In this paper we discuss a specific methodological use of clinical biomarkers in pharmacological measurement: Some biomarkers, called ‘surrogate markers’, are used to substitute for a clinically meaningful endpoint corresponding to events and their penultimate risk factors. We confront the reliability of clinical biomarkers that are used to gather information about clinically meaningful endpoints. Our aim is to present a systematic methodology for assessing the reliability of multiple surrogate markers (and biomarkers in general). To do this we draw upon the robustness analysis literature in the philosophy of science and the empirical use of clinical biomarkers. After introducing robustness analysis we present two problems with biomarkers in relation to reliability. Next, we propose an intervention-based robustness methodology for organizing the reliability of biomarkers in general. We propose three relevant conditions for a robust methodology for biomarkers: (R1) Intervention-based demonstration of partial independence of modes: In biomarkers partial independence can be demonstrated through exogenous interventions that modify a process some number of “steps” removed from each of the markers. (R2) Comparison of diverging and converging results across biomarkers: By systematically comparing partially-independent biomarkers we can track under what conditions markers fail to converge in results, and under which conditions they successfully converge. (R3) Information within the context of theory: Through a systematic cross-comparison of the markers we can make causal conclusions as well as eliminate competing theories. We apply our robust methodology to currently developing Alzheimer’s research to show its usefulness for making causal conclusions.

Other Versions

No versions found

Links

PhilArchive

External links

  • This entry has no external links. Add one.
Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Biomarkers in Psychiatric Disorders.Walter Glannon - 2022 - Cambridge Quarterly of Healthcare Ethics 31 (4):444-452.

Analytics

Added to PP
2020-04-19

Downloads
149 (#160,222)

6 months
95 (#72,972)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Vadim Keyser
California State University, Fresno

Citations of this work

No citations found.

Add more citations

References found in this work

Theory and Evidence.Clark N. Glymour - 1980 - Princeton University Press.
Representing and Intervening.Ian Hacking - 1983 - British Journal for the Philosophy of Science 35 (4):381-390.
Robustness Analysis.Michael Weisberg - 2006 - Philosophy of Science 73 (5):730-742.

View all 14 references / Add more references